%0 Journal Article
%A Radtke, Jan Philipp
%A Giganti, Francesco
%A Wiesenfarth, Manuel
%A Stabile, Armando
%A Marenco, Jose
%A Orczyk, Clement
%A Kasivisvanathan, Veeru
%A Nyarangi-Dix, Joanne Nyaboe
%A Schütz, Viktoria
%A Dieffenbacher, Svenja
%A Görtz, Magdalena
%A Stenzinger, Albrecht
%A Roth, Wilfried
%A Freeman, Alex
%A Punwani, Shonit
%A Bonekamp, David
%A Schlemmer, Heinz-Peter
%A Hohenfellner, Markus
%A Emberton, Mark
%A Moore, Caroline M
%T Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.
%J PLOS ONE
%V 14
%N 8
%@ 1932-6203
%C San Francisco, California, US
%I PLOS
%M DKFZ-2019-02057
%P e0221350 -
%D 2019
%X Risk models (RM) need external validation to assess their value beyond the setting in which they were developed. We validated a RM combining mpMRI and clinical parameters for the probability of harboring significant prostate cancer (sPC, Gleason Score ≥ 3+4) for biopsy-naïve men.The original RM was based on data of 670 biopsy-naïve men from Heidelberg University Hospital who underwent mpMRI with PI-RADS scoring prior to MRI/TRUS-fusion biopsy 2012-2015. Validity was tested by a consecutive cohort of biopsy-naïve men from Heidelberg (n = 160) and externally by a cohort of 133 men from University College London Hospital (UCLH). Assessment of validity was performed at fusion-biopsy by calibration plots, receiver operating characteristics curve and decision curve analyses. The RM`s performance was compared to ERSPC-RC3, ERSPC-RC3+PI-RADSv1.0 and PI-RADSv1.0 alone.SPC was detected in 76 men (48
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:31450235
%R 10.1371/journal.pone.0221350
%U https://inrepo02.dkfz.de/record/144615